The Biden administration has released a proposal to raise standards in nursing homes. Why one expert calls it the most significant development for the industry in decades -- and why it might still not be enough.
The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.
- Marc Kaufman Reporter on the national desk of "The Washington Post"
- Dr. Jerry Avorn Author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
- Alan Goldhammer, PhD Associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
- Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
- Dr. Sandra Kweder Deputy director of the FDA's Office of New Drugs
Most Recent Shows
Legal analyst Kimberly Wehle on the 14th Amendment and whether it can be used to keep Donald Trump off the ballot.
Diva Denyce Graves talks about her storied career and her new push to make opera more diverse -- and more relevant.
Another school year has begun. Diane talks to AP education reporter Bianca Vazquez Toness about the lingering effects of the pandemic on schools, students and learning.